Skip Navigation LinksHome > March 2014 - Volume 21 - Issue 2 > New strategies for relapsed acute myeloid leukemia: fertile...
Current Opinion in Hematology:
doi: 10.1097/MOH.0000000000000018
MYELOID DISEASE: Edited by Martin S. Tallman

New strategies for relapsed acute myeloid leukemia: fertile ground for translational research

Dinner, Shira N.; Giles, Francis J.; Altman, Jessica K.

Collapse Box


Purpose of review: Although frontline treatment of acute myeloid leukemia (AML) achieves high remission rates, approximately 75–80% of patients will either not respond to or relapse after initial therapy. Some patients, generally those who are younger, can be successfully salvaged with second-line chemotherapy followed by allogeneic stem cell transplantation. There is a great need for novel therapies in AML.

Recent findings: Advances in molecular technology recently identified recurrent mutations including mutations of DNMT3A, IDH1/2, and TET2. These mutations represent a major advance in the understanding of leukemogenesis and prognosis, and have enabled the development of targeted therapies.

Summary: Improved knowledge of the molecular pathogenesis of AML has allowed development of therapies targeting epigenetic modulation, intracellular signaling pathways, prosurvival proteins, and the tumor microenvironment.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins


Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.